Browsing: sanofi

Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD

By 0
Singapore, 14 May 2025 – The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils who are on a stable combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate.

Log In or Register as a healthcare professional to read the full article.